An ad hoc committee, under the auspices of the National Academies of Sciences, Engineering, and Medicine's Health and Medicine Division, has been convened to study temporomandibular disorders (TMD) in a project entitled From Research Discoveries to Clinical Treatment.

Temporomandibular disorders (TMD) are the leading cause of chronic orofacial pain. They represent a type of "idiopathic" pain disorder, meaning that the cause or causes are unknown, but research over the decade suggests a genetic component contributing to susceptibility.

The first meeting of the National Academy of Medicine Committee on Temporomandibular Disorders (TMD): From Research Discoveries to Clinical Treatment will be held Tuesday, January 29, 2019 at the National Academy of Sciences building in Washington, D.C.&

The Trial of the Class Action brought by Canadian patients who were implanted with Vitek Proplast TMJ implants, against Health Canada, alleging negligent regulation starts on April 1, 2019 in Toronto.

Funding Opportunities now available for the NIH Common Fund’s Acute to Chronic Pain Signatures program

Aug 29, 2018

The NIH Common Fund’s Acute to Chronic Pain Signatures program aims to understand the biological characteristics underlying the transition from acute to chronic pain and what makes some people susceptible and others resilient to the development of chronic pain. A2CPS is part of the NIH-wide HEAL (Helping to End Addiction Long-term) Initiative, an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis.

Summary: The A2CPS program will collect data from: (1) patients with acute pain associated with a surgical procedure and (2) patients with acute pain from a musculoskeletal trauma such as a broken bone. Neuroimaging, high-throughput biomedical measurements, sensory testing, and psychosocial assessments collected periodically after the acute pain event will form a comprehensive data set to help predict which patients will develop long-lasting chronic pain. The goal of these studies is to identify individual patient features that together, will provide clinically meaningful, predictive “signatures” of transition or resilience to chronic pain.

The purpose of this FOA is to support a Multisite Clinical Center to implement the enrollment and multimodal longitudinal assessment of a large cohort of acute peri-operative pain patients to identify a biosignature for resilience to and the transition from acute to chronic pain.

The purpose of this FOA is to support one Multisite Clinical Center (MCC) to implement the enrollment and multimodal longitudinal assessment of a large cohort of patients with acute pain from a musculoskeletal trauma to identify biosignatures for resilience to and/or the transition from acute to chronic pain.

The purpose of this FOA is to identify and support a Clinical Coordination Center (CCC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The Clinical Coordinating Center is expected to serve as the hub for the Multisite Clinical Centers to support study design, efficiency, progress, and quality, and to coordinate and monitor study implementation across the clinical sites. The Clinical Coordinating Center will lead the consortium in developing and implementing standardized protocols, safety standards, staff training protocols, electronic health record (EHR) data standards, patient phenotyping and testing, and regulatory processes.

The purpose of this FOA is to support the establishment of center(s) that will use cutting edge technologies to perform omics analyses (e.g. metabolomic, lipidomic, proteomic, extracellular RNA) of body fluids collected by the Acute to Chronic Pain Signatures (A2CPS) consortium. The omics data generated, in concert with other patient assessments, will be used to identify biosignatures predictive of susceptibility or resilience to the development of chronic pain.

The purpose of this FOA is to identify and support a Data Integration and Resource Center (DIRC) for the Common Fund Acute to Chronic Pain Signatures (A2CPS) Program. The overall programmatic goal of the DIRC is to integrate the efforts of all funded components of the A2CPS and serve as a community-wide nexus for protocols, data, assay and data standards, and other resources generated by the A2CPS Program.

Applications are due October 24, 2018.

An informational webinar will be held on September 6th, 2018 from 2-4 PM, EST.

The NIH Common Fund encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. These programs are supported by the Common Fund, and managed by the NIH Office of the Director in partnership with the various NIH Institutes, Centers, and Offices.

The National Institutes of Health (NIH) –“The Nation's Medical Research Agency” – includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about the NIH and its programs, visit the NIH website.

This website is for general informational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. This website is not a substitute for such advice, diagnosis, or treatment. You should always consult your doctor if you have questions about your health condition or before starting any treatment. The TMJA is unable to provide doctor referrals and does not endorse any particular health care professional or organization. Reliance on any information provided by the TMJA, TMJA employees, other personss appearing on the website at the invitation of the TMJA, or other visitors to the website is solely at your own risk.